Immunological biomarkers predict HIV-1 viral rebound after treatment interruption

HLA CLASS-I EXPRESSION 0301 basic medicine Anti-HIV Agents 3207 Medical Microbiology 32 Biomedical and Clinical Sciences HIV Infections DETERMINANTS 613 Article 03 medical and health sciences anzsrc-for: 32 Biomedical and Clinical Sciences ANTIRETROVIRAL THERAPY 616 2.1 Biological and endogenous factors Humans anzsrc-for: 3207 Medical Microbiology POPULATION anzsrc-for: 3204 Immunology Science & Technology MORTALITY DISEASE PROGRESSION 3 Good Health and Well Being Viral Load INFECTED INDIVIDUALS CD4 Lymphocyte Count 3. Good health 3204 Immunology Multidisciplinary Sciences Infectious Diseases Withholding Treatment T-CELLS HIV-1 HIV/AIDS Sexually Transmitted Infections Science & Technology - Other Topics Infection Biomarkers RESPONSES
DOI: 10.1038/ncomms9495 Publication Date: 2015-10-09T11:18:00Z
ABSTRACT
AbstractTreatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (148)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....